LENZ Therapeutics (LENZ) Projected to Announce Quarterly Earnings on Thursday

LENZ Therapeutics (NASDAQ:LENZ) is expected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.97) per share and revenue of $4.20 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Tuesday, August 11th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative return on equity of 53.39% and a negative net margin of 586.74%. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $2.38 million. On average, analysts expect LENZ Therapeutics to post ($4.10) EPS for the current fiscal year and ($2.80) EPS for the next fiscal year.

LENZ Therapeutics Stock Up 0.4%

Shares of NASDAQ LENZ opened at $3.15 on Tuesday. The stock has a market cap of $99.07 million, a P/E ratio of -0.77 and a beta of 0.64. The firm’s 50-day simple moving average is $4.19 and its 200 day simple moving average is $8.35. LENZ Therapeutics has a fifty-two week low of $3.06 and a fifty-two week high of $32.13.

Analysts Set New Price Targets

Several research analysts have issued reports on LENZ shares. Piper Sandler dropped their price target on LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, October 19th. Weiss Ratings lowered LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th. Finally, Zacks Research raised LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $23.00.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.